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Aims An excessive production of aldosterone influences outcome in patients with heart failure (HF) and in obese patients.
Findings from laboratory studies suggest that chronic aldosterone blockade maybe more beneficial in abdominally
obese HF-prone rats. In the current study, we investigated if the clinical response to a mineralocorticoid receptor
antagonist in mildly symptomatic HF patients varied by abdominal obesity.
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Methods
and results
A total of 2587 NYHA class II, reduced ejection fraction HF (HFrEF) patients enrolled in the EMPHASIS-HF trial were
randomly assigned to eplerenone and placebo. In this post hoc analysis, patients were categorized according to waist
circumference (WC) (normal if WC < 102 cm in men and< 88 cm in women; abdominal obesity if WC ≥ 102 cm in
men and≥ 88 cm women). The potential statistical interaction between the treatment and WC was assessed on the
primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over
a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both
normal [hazard ratio (HR) 0.77, 95% confidence interval (CI) 0.61–0.98, P = 0.03] and increased (HR 0.48, 95% CI
0.37–0.63, P < 0.0001) WC subgroups, but the latter patients appeared to receive greater benefit than patients with
normal WC (P for interaction = 0.01). This suggests a significant quantitative (treatment effect varies in magnitude
by subgroup, but is always in same direction) rather than a qualitative interaction (direction of the treatment effect
varies by subgroup) between eplerenone andWC in the adjusted analysis. Mean doses of eplerenone, blood pressure
and serum potassium changes and adverse events were similar between WC subgroups.
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Conclusion In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although
the benefit appeared to be more pronounced among those with abdominal obesity. The findings are potentially
hypothesis generating and need to be replicated in other HFrEF populations.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Obesity is recognized as a cardiovascular risk factor and the
worldwide epidemic of obesity parallels the one observed for
heart failure (HF).1–3 It is associated with increased risk of car-
diorenal disease, including hypertension, coronary artery disease
and adverse cardiac remodelling (left ventricular hypertrophy
and dilation), and progression towards HF.4 In addition obese
subjects have higher aldosterone levels, which may result in min-
eralocorticoid receptor (MR) over-activation. Reciprocally, higher
aldosterone levels have been implicated in the development and
maintenance of obesity.5–7
Mineralocorticoid receptor antagonist (MRA) therapy improves
outcomes in patients with chronic systolic HF with mild symp-
toms (EMPHASIS-HF trial), acute symptomatic systolic HF in
post-myocardial infarction (EPHESUS trial) and in severe NYHA
class III–IV systolic HF (RALES trial).8–11 However, to the best of
our knowledge the influence of established overweight or obesity
on the response to MRAs is unknown. Studies in obese non-HF
patients with or without associated metabolic disorder12 suggested
that MRA therapy improved left ventricular function and myocar-
dial abnormalities with concurrent decreases of circulating fibrotic
markers. Knowing that visceral fat is a source of serum aldosterone
and that several experimental studies7,13–15 have implicated aldos-
terone as an important mediator of obesity-related cardiovascular
risk, we have recently published the first experimental data sug-
gesting that, as compared to leaner counterparts, viscerally obese
HF-prone rats may further benefit from chronic MRA treatment.16
Yet no study has specifically evaluated whether clinical response to
a MRA over a long follow-up period might be better in HF patients
with vs. without abdominal obesity.
In this context, we sought for the first time to evaluate the
interaction between increased adiposity estimated by the waist
circumference (WC) and body mass index (BMI, as reference
obesity measurement parameter) and the clinical benefit from
the MRA eplerenone in patients with congestive HF receiving
recommended therapy for systolic HF (ejection fraction<35%) and
enrolled in the EMPHASIS-HF trial.11
Methods
The design, patient eligibility criteria, study procedure and main results
of the EMPHASIS-HF study have been previously reported.11 In brief,
in this randomized double-blind trial, patients with NYHA class II HF
and an ejection fraction of no more than 35% (HFrEF) were randomly
assigned to receive eplerenone (up to 50mg daily) or placebo, in
addition to recommended therapy.
Study outcomes
The same primary and secondary outcomes were used in the cur-
rent analysis as in the main study.11 Briefly, the primary outcome was
the composite of death from cardiovascular causes or first hospitaliza-
tion for HF. The pre-specified adjudicated secondary outcomes were,
respectively, all-cause death, cardiovascular death and hospitalization
for HF. For continuous variables, the baseline value was defined accord-
ing to the EMPHASIS-HF statistical analysis plan as the measurement ..
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.. that was made on the closest date prior to the study medication
starting date. If there were more than one measurement made on the
same date, the average value of these data was calculated and used as
the baseline measurement.
Because the following variables did not fulfil the assumption of
log-linearity, WC and BMI were not analysed as continuous variables
but as categorical variables.
Waist circumference
Baseline measurement ofWCwas performed by a tape measure placed
around the subject’s bare abdomen just above the subject’s hipbone, at
the level of the subject’s navel, when the relaxed subject exhaled. The
tape measure was positioned parallel to the floor without compressing
the subject’s skin. Values were considered aberrant and were excluded
from the data analysis when WC< 60 cm.
Subjects were divided into twoWC groups according to the Ameri-
can Heart Association (AHA) defined cut-offs.17 Men and women with
WC values <102 and <88 cm, respectively, were considered to have a
normal WC (NWC group), whereas those with WC values ≥102 and
≥88 cm, respectively, were considered to have high WC (HWC group)
and harbour an abdominal obesity. Subjects were further categorized
according to WC quintiles taking into account sex differences.
Body mass index
Body mass index is defined as the weight in kilograms divided by the
square of the height in metres (kg/m2). BMI values were considered
missing when height or weight measures were not reported. Obesity
was defined according to the World Health Organization BMI classifi-
cation (http://apps.who.int/bmi/index.jsp?introPage=intro_3.html): BMI
values≥ 30 kg/m2 were classified as obese patients while BMI values
<30 kg/m2 characterized normal-weight and overweight patients.
Statistical analysis
Waist circumference and BMI were the key explanatory variables. Con-
tinuous variables are expressed as mean± standard deviation (SD),
categorical variables as frequencies (percentage). Comparisons of base-
line characteristics between WC or BMI groups were performed using
Student’s t-test, Mann–Whitney, or 𝜒2 test as required. Risk probabil-
ities were calculated using the Kaplan–Meier method and plotted as
survival curves.
Hazard ratios (HRs) and respective 95% confidence intervals (CIs)
were estimated using univariable and multivariable Cox proportional
hazards regression models. Assumptions of log-linearity, absence of
multicollinearity and hazards proportionality were thoroughly verified.
Interactions between BMI or WC and eplerenone effect on out-
comes were assessed by introducing an interaction term (BMI or
WC variable× eplerenone) in crude (i.e. BMI or WC, eplerenone,
BMI or WC× eplerenone) and adjusted models. The following can-
didate covariates were considered for adjustment: age, gender, heart
rate, systolic blood pressure, left ventricular ejection fraction, QRS
duration, medical history (hospitalization for HF, hypertension, angina
pectoris, myocardial infarction, coronary angioplasty, coronary artery
bypass surgery, atrial fibrillation or flutter, diabetes mellitus, stroke),
device therapy (implantable cardioverter-defibrillator, cardiac resyn-
chronization therapy, implantable cardioverter-defibrillator with car-
diac resynchronization), blood sodium, blood potassium, estimated
glomerular filtration rate and use of diuretics, angiotensin-converting
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enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),
beta-blockers, and lipid-lowering agents. Among these candidate
covariates, variables significantly associated with the outcome of inter-
est with a P-value <0.15 on univariable Cox regression18 were further
selected using an interactive backward selection process. Only the
covariates associated with the outcome of interest with a P-value<0.05
were retained in multivariable models.
In addition, we evaluated the functional form of the interaction
between treatment and WC/BMI with regards to the risk of outcomes
using WC/BMI as a non-linear continuous variable. To do so, we
used restricted cubic splines and plotted the HRs of treatment effect
according to WC/BMI calculated from the Cox model.
Adverse events and those leading to permanent study drug with-
drawal were presented according to WC or BMI category groups.
Statistical interaction has come into increasing use in trial analysis.
Given the low power of interaction tests, selected a priori a 0.10 cut-off
threshold for the interaction P-value has been used. As a consequence,
a P -value of <0.05 was considered statistically significant for the main
effects and <0.10 for the interaction terms.
All analyses were performed using SAS software version 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
Clinical characteristics
Of the 2737 patients randomized in EMPHASIS-HF, 2579 were
included in the WC analysis (158 patients had a missing or
implausible WC value). Median WCs were 100 cm [interquartile
range (IQR) 92–108] and 94 cm (IQR 85–104) in men and women,
respectively, and 1295 patients (50.2%) had a HWC (abdominal
obesity if WC≥102 cm for men and≥ 88 cm for women). The
remaining 1284 individuals had a NWC (if WC< 102 cm for men
and< 88 cm for women) (Table 1; Supplementary material online,
Table S1). Patients with a HWC had more obesity-related disorders
such as hypertension, atrial fibrillation, and diabetes mellitus, as
compared to patients with NWC (Table 1). However, there were
no clinically significant differences between patients allocated to
eplerenone or placebo within the two WC subgroups (Table S1).
Of the 2737 patients randomized in EMPHASIS-HF, 2722 were
included in the BMI analysis (15 patients had a missing or implausi-
ble BMI value). The median BMI was 27 kg/m2 (IQR 24–30) and 739
patients (27.1%) had global obesity with BMI≥ 30 kg/m2 and 1983
(72.9%) a BMI< 30 kg/m2. Similar to patients with HWC, those
with a high BMI had more obesity-related disorders as compared
to patients with BMI< 30 kg/m2 (Table 1).
The median follow-up duration among all patients was 21
months (IQR 10–33 months).
Eplerenone safety profile across
subgroups
Adverse events leading to eplerenone withdrawal occurred in
101 (15.7%) NWC patients as compared to 74 (11.5%) HWC
patients (P= 0.034) leading to a P-value for the interaction of 0.01
(Supplementary material online, Table S2). Hyperkalaemia adverse
events and hyperkalaemia leading to study-drug discontinuation
occurred equally in WC and BMI eplerenone subgroups (Table S2). ..
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.. Mean doses achieved across subgroups
The mean dose of eplerenone did not differ between WC
subgroups (P= 0.67). Among patients assigned to eplerenone,
61.4% and 62.3% of the HWC and NWC groups, respectively,
received the highest daily dose (50mg daily, P= 0.81). Likewise, the
mean dose of eplerenone did not differ between BMI subgroups
(P= 0.79) and 60.8% of the BMI≥ 30 kg/m2 patients against 61.6%
of the BMI< 30 kg/m2 groups received the highest daily dose of
eplerenone (50mg daily, P= 0.96).
Effect of eplerenone on clinical outcomes
Overall, there were fewer primary endpoints in the eplerenone
group in EMPHASIS-HF (multivariable HR 0.63, 95% CI 0.52–0.75).
This was also the case for other outcomes, including all-cause
mortality (HR 0.76, 95% CI 0.61–0.94), cardiovascular mortality
(HR 0.73, 95% CI 0.58–0.93), and hospitalization for HF (HR 0.59,
95% CI 0.48–0.73) (Figures 1 and 2).
When analysing according to WC and BMI anthropomorphic
subgroups, no differential effect of the treatment was observed
on blood pressure, heart rate, body weight, and serum potassium
levels, expressed as changes from baseline to month 1 and month
5 post-randomization (data not shown).
Interaction between abdominal obesity
and the effects of eplerenone
The modifying effect of abdominal obesity on the impact of
eplerenone for each outcome is shown in Figures 1 and 2. The effect
of eplerenone on the primary outcome was significant in both
patients with HWC (multivariable HR 0.48, 95% CI 0.37–0.63) and
in patients with NWC (multivariable HR 0.77, 95% CI 0.61–0.98),
but significantly stronger in the HWC group as demonstrated by a
P-value for the interaction of 0.01 (Figures 1A and 2A).
Importantly, abdominal obesity, i.e. HWC, was not associated
with the primary outcome in the placebo group (multivariable HR
0.96, 95% CI 0.76–1.20) whereas it was associated with lower
rates for the primary events in the eplerenone group (multivariable
HR 0.60, 95% CI 0.45–0.80), resulting in a significant interaction
between eplerenone and HWC in the adjusted analysis (P= 0.01).
Overall, similar patterns were observed for the secondary
outcomes but the interaction between eplerenone and HWC
reached statistical significance only for the secondary outcomes
of death from cardiovascular causes and hospitalization for HF (P
for interaction 0.09 and 0.07, respectively) (Figure 2 and Table 2).
In addition, we identified a significant interaction in men between
treatment and WC within the model using restricted cubic
splines (P-value for the interaction is 0.025 in the adjusted model,
Figure 3A). The shape of the association is difficult to assess in
women given the wide Cls resulting from the small number of
patients within the subset of female patients. In this subset, the
interaction did not reach statistical significance (P= 0.30 in the
adjusted model, Figure 3B). Likewise the interaction between treat-
ment and BMI for both genders using restricted cubic splines did
not reach significance (P= 0.15 in the adjusted model, Figure 3C).
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Table 1 Baseline characteristics of the patients according to morphometric parameter subgroups
Characteristics NWC
n=1284
HWC
n= 1295
P-value BMI< 30 kg/m2
n= 1983
BMI≥ 30 kg/m2
n= 739
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 69.1± 7.9 68.2± 7.3 0.003 69.2± 7.7 67.0± 7.2 <0.0001
Male gender (%) 85.4 70.0 <0.0001 79.7 72.5 <0.0001
BMI (kg/m2) 25± 3 31± 4 <0.0001 25± 3 34± 4 <0.0001
Weight (kg) 70± 12 89±16 <0.0001 73±12 97±14 <0.0001
Height (cm) 169± 9 170± 10 <0.0001 169± 9 170±10 0.22
WC (cm) 90± 8 109± 10 <0.0001 94±10 112±11 <0.0001
Heart rate (b.p.m.) 71.0±12.2 72.4±12.4 0.01 71.5±12.4 72.4± 12.6 0.16
Systolic blood pressure (mmHg) 122±17 126± 16 <0.0001 123±17 127±16 <0.0001
Systolic blood pressure≥ 130mmHg (%) 38.2 45.2 0.0004 38.8 48.7 <0.0001
Left ventricular ejection fraction (%) 26± 5 26± 4 0.006 26± 5 26± 4 0.03
Left ventricular ejection fraction< 35% (%) 98.7 97.7 0.07 98.2 98.1 0.83
QRS duration (ms) 121± 46 123± 44 0.23 121± 44 122± 46 0.90
Ischaemic heart disease (%) 69.9 69.3 0.74 69.9 66.7 0.10
Medical history (%)
Hospitalization for heart failure 53.1 52.0 0.59 52.3 53.5 0.61
Hypertension 59.4 74.4 <0.0001 62.7 76.6 <0.0001
Angina pectoris 43.5 45.3 0.34 42.1 47.2 0.02
Myocardial infarction 51.9 50.7 0.56 51.3 48.3 0.16
PCI 21.3 21.8 0.76 22.2 20.7 0.41
CABG 20.7 17.0 0.02 19.7 16.8 0.09
Atrial fibrillation 28.0 34.1 0.0007 28.8 36.4 0.0001
Diabetes mellitus 27.0 36.2 <0.0001 28.7 38.6 <0.0001
Stroke 8.8 10.4 0.17 9.3 10.9 0.20
Biology
Estimated GFR (ml/min/1.73m2) 71± 22 71± 22 0.92 70± 22 72± 22 0.07
Estimated GFR< 60ml/min/1.73m2 (%) 34.5 32.2 0.21 34.2 31.0 0.11
Potassium (mmol/L) 4.3± 0.4 4.3± 0.4 0.05 4.3± 0.4 4.3± 0.4 0.52
Sodium (mmol/L) 139.8± 4.2 140.4± 3.8 <0.0001 139.9± 4.1 140.6± 3.5 <0.0001
Device therapy (%)
Implantable cardioverter-defibrillator 12.9 14.4 0.27 13.4 13.1 0.86
Implantable cardioverter-defibrillator with
cardiac resynchronization
6.0 7.6 0.13 6.2 7.4 0.28
Cardiac resynchronization therapy 2.1 2.5 0.45 2.4 1.8 0.35
Medications at randomization visit (%)
Eplerenone 50.2 49.7 0.80 49.2 51.8 0.22
Diuretic 84.3 86.6 0.10 84.8 87.2 0.12
ACE inhibitor or ARB 92.1 94.4 0.02 93.3 93.8 0.65
Beta-blocker 87.4 87.4 1.00 86.7 88.7 0.17
Lipid-lowering agent 63.3 62.2 0.60 63.5 61.5 0.33
Values are± SD or percentage.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor type II blocker; BMI, body mass index (characterizing global obesity when ≥30 kg/m2); CABG, coronary
artery bypass grafting; GFR, glomerular filtration rate; HWC, high waist circumference (≥102 cm for men and ≥88 cm for women characterizing abdominal obesity); NWC,
normal waist circumference (<102 cm for men and <88 cm for women); PCI, percutaneous coronary intervention; WC, waist circumference.
Overall, both WC groups derived significant benefit from
eplerenone for the primary outcome and hospitalization for HF
with quantitatively greater benefits derived from the treatment
in patients with abdominal obesity from the HWC subgroup.
A lower dropout rate was observed in patients randomized
to eplerenone when they had HWC, which could contribute
to the higher treatment effect observed in this subgroup,
and further suggests a net higher benefit to risk ratio in the
HWC group. A sensitivity analysis censoring the follow-up
up to the time of permanent drug discontinuation yielded ..
..
..
..
..
..
..
..
..
..
..
..
..
..
. interaction still suggesting a higher benefit to risk ratio in the
HWC group.
While analysing the EMPHASIS-HF population using WC
quintiles, we observed lower HR for the primary outcome in
patients within the 3rd to 5th quintiles (i.e. ≥97 cm in men and
≥90 cm in women) than in patients within the first two quin-
tiles (Supplementary material online, Table S3) with a significant
P-value for interaction between eplerenone and WC (P= 0.09).
Interestingly, multivariable HR in the 3rd to 5th quintiles ranged
from 0.47 (95% CI 0.32–0.71) to 0.53 (95% CI 0.34–0.82)
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Figure 1 Cumulative Kaplan–Meier estimates of rates of the primary and secondary outcomes according to the four study groups. CV,
cardiovascular; EPL, eplerenone; HF, heart failure; PLA, placebo; WC, waist circumference with NWC for normal waist circumference group
(waist circumference<102 cm for men and< 88 cm for women) and HWC for high waist circumference group characterized by the presence
of abdominal obesity (waist circumference≥ 102 cm for men and≥ 88 cm for women).
whereas the HRs of the first two quintiles were 0.70 (95%
CI 0.49–1.00) and 0.94 (95% CI 0.64–1.37), respectively. Of
note, these cut-offs (i.e. ≥97 cm in men and ≥90 cm in women)
within the EMPHASIS-HF population were below and above
the cut-offs defining abdominal obesity in men and women,
respectively.
Interaction between body mass index
and the effects of eplerenone
The benefit of eplerenone on the rate of the primary outcome
seemed to be greater in obese (BMI≥ 30 kg/m2) patients (mul-
tivariable HR 0.49, 95% CI 0.35–0.71) than in patients with
BMI< 30 kg/m2 (multivariable HR 0.69, 95% CI 0.57–0.83), but ..
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. the difference was not as marked as for WC and the P-value
for interaction between BMI and eplerenone was greater than
0.10 (P= 0.11, Figure 2; Table 2). Similar observations were done
for secondary outcomes, with no significant interaction in the
adjusted analyses between BMI and the effect of eplerenone
(Table 2). When analysed according to the median BMI value
of 27 kg/m2, the benefit of eplerenone on the rate of the pri-
mary outcome was greater in patients with BMI≥ 27 kg/m2
(multivariable HR 0.50, 95% CI 0.38–0.65) than in patients with
BMI< 27 kg/m2 (multivariable HR 0.76, 95% CI 0.61–0.94; P
for interaction= 0.018) (Supplementary material online, Table
S4). These results of BMI analyses with a cut-off defined at
27 kg/m2 and 30 kg/m2 (Table 2 and Supplementary material
online Table S4, respectively) are confirmed by the shape of the
© 2017 The Authors
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Variable
No.
events/
patients
Hazard ratio
(95%CI)
P-value 
for interaction
Overall 508/2340
0.01CW
NWC 276/1170
HWC 232/1170
0.11IMB
<30 404/1741
≥30 120/646
Variable
No.
events/
patients
Hazard ratio
(95%CI)
P -value  
for interaction
Overall 333/2339
WC 0.13
NWC 191/1170
HWC 142/1169
BMI 0.73
<30 263/1698
≥30 69/632
Variable
No.
events/
patients
Hazard ratio
(95%CI)
P-value
for interaction
Overall 286/2343
0.09CW
NWC 163/1172
HWC 123/1171
BMI 0.93
<30 226/1700
≥30 59/633
Variable
No.
events/
patients
Hazard ratio
(95%CI)
P-value
for interaction
Overall 381/2421
WC 0.07
NWC 191/1212
HWC 170/1209
BMI 0.25
<30 301/1853
≥30 86/699
Hospitalization for heart failure or
death from cardiovascular causes 
All-cause death 
Death from cardiovascular causes  Hospitalization for heart failure 
A B
C D
Figure 2 Hazard ratios for studied outcomes with eplerenone vs. placebo in the overall population and according to specified subgroups of
waist circumference (WC) and body mass index (BMI). The subgroups are based on baseline demographic and clinical characteristics. Values
within the entire population are presented in grey. Values within the normal ranges of WC (NWC, i.e. <102 and < 88 cm for men and women,
respectively) and BMI (<30 kg/m2) are presented in black and increased values in white (HWC, i.e. ≥ 102 and ≥ 88 cm for men and women,
respectively, and BMI ≥ 30 kg/m2). Presented data are the results of multivariable model analysis adjusted for statistically significant covariates
among those listed and tested in the statistical analysis section. Thus, the total number of patients (2340) is inferior in this figure to the number
of 2579 in Table 2 as the result of missing values in some patients.
association in adjusted model between eplerenone and the
primary outcome according to the value of BMI when used as a
continuous variable (Figure 3C). Risk of cardiovascular diseases or
hospitalization for HF is higher for values around 25 kg/m2, while
it decreases until a value of 30 kg/m2, and then remains steady ..
..
..
..
..
..
.. (Figure 3C). Likewise, the benefit of eplerenone on the rates of
hospitalization for HF was greater in patients with BMI≥ 27 kg/m2
(multivariable HR 0.44, 95% CI 0.33–0.62) than in patients with
BMI< 27 kg/m2 (multivariable HR 0.68, 95% CI 0.52–0.88; P for
interaction= 0.051) (Table S4).
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Eplerenone treatment effect according to WC in women
Eplerenone treatment effect according to body mass index in both genders
P-value for interaction 0.025
P-value for interaction 0.30
P-value for interaction 0.15
Eplerenone treatment effect according to WC in menA
B
C
Figure 3 Eplerenone treatment effect according to morphometric parameters using restricted cubic spline. Restricted cubic splines were
drawn for the composite primary outcome to model the interaction between treatment and waist circumference (WC) (A and B) or body
mass index (C) when both morphometric parameters were used as a continuous variable. Interactions are presented for men (A), women (B)
and both genders (C) in adjusted models. The continuous lines represent the hazard ratio and the dotted lines represent the confidence limits
for the considered hazard ratio.
Discussion
The main finding of our post hoc analysis of the EMPHASIS-HF
data suggests that patients with HFrEF and with mild
symptoms and abdominal obesity derive greater bene-
fit from eplerenone than those who are not obese or
overweight. All HFrEF patients derived benefits from eplerenone
in the EMPHASIS-HF trial, but the greater benefits afforded by ..
..
..
..
..
..
..
..
..
..
..
.. eplerenone in HWC patients were substantiated by the significant
interaction between WC and eplerenone for three out of
the four studied outcomes. This characterized for the first time a
quantitative rather than a qualitative interaction between adiposity
and the response to MRA therapy. Importantly, this greater benefit
occurred with the use of similar doses of eplerenone and overall
the benefit/risk ratio was more favourable since the rate of adverse
events was not different among WC subgroups. Altogether this
© 2017 The Authors
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post hoc analysis of EMPHASIS-HF suggests that abdominal obesity
estimated by WC measurement could be a simple and straight-
forward classifier identifying a subset of patients with HFrEF that
might derive greater benefit fromMRA therapy. Despite the known
adverse impact of obesity on most of the HF risk factors, our
results suggest a better prognosis for patients with abdominal obe-
sity, i.e. an obesity paradox. Thus, our results suggest for the first
time that part of the known obesity paradox observed in HF tri-
als might be explained by the greater benefits derived by obese
patients from their HF MRA treatment.
The deleterious impact of excessive aldosterone/MR activation
in the heart has been extensively documented during this past
decade. Both cortisol and aldosterone adversely affect the cardio-
vascular events via the activation of the MRs in the heart, blood
vessels, kidney, and other sites.19 Notably, high levels of aldos-
terone promote the development of interstitial cardiac fibrosis,
promote platelet aggregation, and contribute to endothelial dys-
function, in part by reducing nitric oxide bioavailability, and favour
hypertension, chronic kidney disease, and concentric left ventricu-
lar hypertrophy in the general community.20 Furthermore, MR acti-
vation in macrophages has been demonstrated to promote coro-
nary and systemic inflammation, particularly in the initial response
to reperfusion injury after ischaemic injury.21,22 Collectively, these
studies have justified the targeting of MR as a new approach for
the treatment of HF patients.8,11,23 The mechanism of action of
MRAs in HF is multiple, including anti-inflammatory, anti-fibrotic
and anti-remodelling properties, with a decrease in sympathetic
drive and improvement in heart rate variability.24–26 It could be
in part attributed to the increased MR activation and more pro-
nounced production of its ligands in the failing human heart.4,27,28
Experimental and clinical studies suggest that MR over-activation
in hyperphagic conditions29 and high fat diet-induced obesity may
precipitate cardiac remodelling and HF development.14,30,31 In fact,
all components of the renin–angiotensin–aldosterone system
(RAAS) are expressed in adipose tissue and their gene expres-
sion has been found increased in adipose tissues of both obese
animal models and obese humans.7,32,33 The increments in body
weight and overall obesity are known to result from chronic
positive energy balance, a condition which is known to increase
MR expression and further favour the development of adipose
tissue inflammation and fibrosis.30 We recently demonstrated that
chronic eplerenone treatment delayed cardiac remodelling and
HF onset in both lean and obese spontaneously hypertensive HF
rats but that obese rats presenting a higher aldosterone level
further benefited from MRA treatment through improvement
of their obesity, dyslipidaemia and myocardial fibrosis.16 Further
experimental studies have demonstrated that the benefits of
MR blockade included reduced obesity-related cardiac fibrosis,
coronary microvascular disorders, cardiac oxidative stress, and
systemic inflammation.14,31 Small exploratory clinical studies
further suggested beneficial effects of spironolactone on left
ventricular dysfunction in obese individuals without other
co-morbidities and in patients with metabolic syndrome, which
supports our observation of a more pronounced clinical ben-
efit of MRA therapy in overweight to obese individuals.12,24 It
also suggests that overweight to obese HF patients may derive ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. great benefit from MRA at least in part because of their high
inflammatory and fibrotic clinical status.34–36
This is of strong interest when considering that in the USA
approximately one-half to two-thirds of HF patients are overweight
or obese.37 Interestingly, aldosterone was proposed to promote
adipogenesis by inducing peroxisome proliferator-activated recep-
tor 𝛾 expression, while increased adiposity is known to have
adverse effects on left ventricular structure and function, and
other risk factors of HF, including hypertension and coronary
artery disease.14,38 Thus, although speculative in clinic but based
on strong experimental evidence, one tentative explanation of
the better response to eplerenone of HF patients with abdominal
obesity might be that these patients have higher aldosterone levels
associated with hyper-secretion of trophic factors from the vis-
ceral adipose tissue.5,39 The observed better discriminative power
of the WC parameters in defining the best responder group of
HFrEF to eplerenone as compared to BMI might be explained in
part by the fact that the RAAS has been described to have variable
activity depending on the adipose tissue location. A high RAAS
activity has been reported in abdominal adipocytes, which are
more closely associated with aldosterone biosynthesis and where
angiotensinogen and angiotensin II receptor gene expression levels
are high. A lower RAAS activity was reported in gluteofemoral
adipose tissue, which may explain why the fat from this latter
location is less metabolically active.40
Adipose tissue is considered as an endocrine organ influencing
the maintenance of the body metabolic and inflammatory home-
ostasis, especially when located in close vicinity to the heart, kidney,
liver and the skeletal muscle. The development of visceral fat tis-
sue results in crucial endocrine interactions with those vital organs
that may lead to their structural and functional alterations.41,42
While largely used to classify obesity, a clear limitation of BMI
is that it is unable to distinguish between increased body fat con-
tent and increased lean body mass (breakdown of body compo-
sition) and cannot indicate where adiposity preferentially devel-
ops as it is accountable for the characterization of global obe-
sity. Our results highlight the different relevance of these two
anthropometric parameters, and confirm that BMI and WC are
not characterizing the same type of adiposity. Altogether, a total of
668 EMPHASIS-HF patients were ‘misclassified’ when using BMI:
626 of them were non-obese (BMI< 30 kg/m2) but harboured
abdominal obesity (HWC) and 42 of them were classified obese
(BMI≥ 30 kg/m2) but had NWC. These are the patients causing a
difference in the results between BMI and WC parameters, lead-
ing to the statistically significant results for the interaction in WC
but not in BMI subgroups. Not all types of adipose fat depot are
alike and can differ by their location (gynoid, android, visceral,
subcutaneous, overall) and degree (from overweight up to mor-
bid obesity). Numerous imaging tools such as dual-energy X-ray
absorptiometry, bioelectrical impedance analysis, and magnetic res-
onance imaging, and anthropometric measures such as BMI and
WC can discriminate between them. Whether imaging data would
better define fat deposition and, thus, better refine the subsequent
risk is beyond the scope of our study, but WC is such an easy
low-cost biomarker to access that its use in general clinic should
be warranted.
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Moreover, weight variation in HF patients is very much depen-
dent on fluid retention, and the resulting congestion may mostly
impact BMI and, to a lesser extent, WC. This suggests that the
latter parameter might be more reliable in the context of HF. Our
results suggest for the first time that the specific location of the
excess of adiposity represents an important matter when treating
HF patients.
While still requiring replication, the differential findings reported
for WC and BMI with regards to patient response to eplerenone
are consistent with the large body of literature suggesting that,
depending on their location, adipose tissue deposits present dis-
tinct metabolic and inflammatory properties. While both subcu-
taneous and visceral adipose tissues are considered as endocrine
organs, visceral adipose tissue has especially been shown to
secrete adipocytokines and other vasoactive substances, includ-
ing aldosterone,25,26 and has been associated with higher mor-
tality than overall obesity defined by BMI.43,44 The increase in
either or both types of fat deposit (subcutaneous and visceral)
participates in the development of abdominal obesity, which is
readily and easily measurable with WC. Interestingly, our data
show no differential effect of the treatment on blood pressure,
heart rate, body weight and serum potassium levels, according to
WC anthropomorphic subgroups (not shown), and hyperkalaemia
adverse events, including those leading to study drug discontin-
uation, occurred equally in WC eplerenone subgroups. In addi-
tion, adverse events leading to eplerenone withdrawal occurred
significantly less frequently in patients with increased abdominal
adiposity. Taken together, our results suggest that the benefit/risk
ratio of eplerenone therapy is higher in patients with abdominal
obesity.
Even though not verified here (the absence of available biosam-
ples precluded us from reconciling the levels of MR ligands and the
degree of abdominal adiposity in the EMPHASIS-HF patients), in
clinic plasma aldosterone concentration correlated with increased
adiposity measured by BMI and was associated with the develop-
ment of metabolic syndrome with increased WC in the Framing-
ham and African-American populations.27,28 It was thus expected
that EMPHASIS-HF obese patients presented worse clinical char-
acteristics as compared to their lean counterparts. While over-
weight and obesity have been shown to increase the risk for
cardiovascular disease in the general population, reduced mor-
tality in the HF population with higher BMI values has been
demonstrated and referred to as the obesity paradox.45,46 Clark
et al. demonstrated such paradox in an advanced HF cohort (left
ventricular ejection fraction < 25%) and increased WC was mostly
associated with improved outcomes in advanced HF.37,43
Our results suggest an improved response to MRA treatment
of EMPHASIS-HF patients as one out of many other possible
contributors to the obesity paradox. Indeed, such paradox, also
described in other pathophysiological conditions, varies according
to (i) aetiology of the wide range of clinical phenotypes observed
in different HF cohorts restricting the protective effect of obesity
to patients with non-ischaemic HF; (ii) patient gender; (iii) patient
age; (iv) left ventricular ejection fraction; (v) cumulative exposure
to excess adiposity and resulting metabolic reserve; and (vi)
presence of diabetes.36,38,46–50 ..
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.. One could extrapolate that what is called the HF obesity
paradox38,43,45,47–49 described in other HF trials might also be a
consequence of HF therapy being more effective in obese patients.
This is at least suggested by the results of our study where abdom-
inally obese patients are better responders to MR antagonism than
leaner participants. Interestingly, this potentially better response
to RAAS inhibitors-based therapy is also suggested in the placebo
group where more than 90% of enrolled patients are already
treated with ACE inhibitors or ARBs and where increased adipos-
ity was not significantly associated with worsening outcomes. In
other reports mentioning this HF obesity paradox phenomenon,
the association of BMI with outcomes was studied while adjust-
ing for the background medical therapy, but the interactions of
BMI with therapy are yet to be reported. Thus, in-depth evalua-
tion of the proposed paradoxical effect of obesity in HF patients
as compared to the general population taking into account expo-
sure to therapy is now required to validate our hypothesis. Future
studies should explore the potential relationship between RAAS
inhibition and the obesity paradox taking into account that our
study was based on the cut-offs for WC and BMI that have been
defined for their predictive value of health risks only, and not for
their capacity to predict the response to a given drug. Further anal-
ysis in larger populations should be considered to challenge and
potentially redefine these cut-offs in order to use WC and BMI as
stratifying biomarkers when prescribing MRA therapy.
Our findings should be regarded as hypothesis generating for
future studies that should be designed to confirm whether HF
patients with increased adiposity, i.e. patients characterized by ele-
vated MR ligand secretion, are potentially the best responders
to MRA therapy. Because EMPHASIS-HF patients presenting an
abdominal obesity derive greater benefit from eplerenone, future
investigation should evaluate how the greater response to MRA
therapy could contribute to and partly explain the so-called ‘obe-
sity paradox’ observed in HF populations.38,42,51 Our results call
upon further investigations of obesity-associated measurements
as potential straightforward classifiers predicting the therapeutic
response to MRAs in HF patients and in other cardiovascular dis-
eases and their respective risk factors for which MR activation
has been implicated. More specifically, it is tempting to explore
whether increased adiposity may also help identify responders to
MRA therapy among HF patients with preserved ejection fraction,
an important category of HF patients in much need of novel effec-
tive therapies. Indeed, recently reported neutral results of clinical
trials using MRA in HF patients with preserved ejection fraction
have been so far explained by international geographic variation.52
Regarding our results, event rates should be analysed according to
differences in anthropomorphic parameters of the Russian, Geor-
gian and American patients enrolled in the TOPCAT trial.23
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Baseline characteristics of patients according to waist
circumference and to treatment per subgroup of waist circumfer-
ence.
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Table S2. Selected investigator-reported adverse events and those
leading to permanent withdrawal of the study drug, according to
study groups.
Table S3. Association between eplerenone and outcomes
depending on waist circumference.
Table S4. Association between eplerenone and outcomes
depending on body mass index.
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